Biotech · Private company
Adamas Pharmaceuticals, Inc.
Track this companyFree. Adds Adamas Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials60 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- 240mg Amantadine HCl ER tabletsPhase 3 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- 320mg Amantadine HCl ER tabletsPhase 3 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- ADS-5102Phase 3 · DyskinesiaClinicalTrials.gov · fetched Nov 12, 2026
- ADS-5102, 137 mgPhase 3 · Walking ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- ADS-5102, 274 mgPhase 3 · Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- ADS-5102, 274 mgPhase 3 · Walking ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- amantadine HCl ERPhase 3 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's DiseasePHASE4 · COMPLETED · started Nov 5, 2020ClinicalTrials.gov NCT04387773 · fetched Nov 12, 2026
- A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking ImpairmentPHASE3 · COMPLETED · started Jul 18, 2018ClinicalTrials.gov NCT03567057 · fetched Nov 12, 2026
- Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking ImpairmentPHASE3 · COMPLETED · started Mar 29, 2018ClinicalTrials.gov NCT03436199 · fetched Nov 12, 2026
- Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.PHASE3 · TERMINATED · started Aug 18, 2014ClinicalTrials.gov NCT02153645 · fetched Nov 12, 2026
- Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LIDPHASE3 · TERMINATED · started Jul 30, 2014ClinicalTrials.gov NCT02153632 · fetched Nov 12, 2026
- Open-Label Safety Study of ADS-5102 in PD Patients With LIDPHASE3 · COMPLETED · started Jul 1, 2014ClinicalTrials.gov NCT02202551 · fetched Nov 12, 2026